Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management
Paris (France), Cambridge (Massachusetts, United States), January 2, 2020, 6
p.m. CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company with a primary focus on the development of its lead drug
candidate, Sarconeos (BIO101), for the treatment of neuromuscular diseases,
today announces the appointment of Evelyne Nguyen as Chief Financial Officer
(CFO) and internal reorganization to strengthen the Company's senior management
The Company has appointed Evelyne Nguyen as CFO effective on January 6th. Ms.
Nguyen has over 25 years of healthcare and finance experience. She joins from
ANM Partners where she was a Senior Corporate Finance Advisor. In this role she
worked with a number of life science companies providing strategic counsel as
well as financial and fund-raising support. Evelyne also had significant
business development experience in Asia, including China. During her career Ms.
Nguyen has worked in positions of increasing responsibility in Finance at a
number of biotech and pharma companies including LFB Group, where she was CFO-
Senior Vice President Finance and Strategy and Bristol Myers Squibb. Ms. Nguyen
replaces Daniel Schneiderman, who has left the company to pursue other career
Biophytis has also appointed Pierre J. Dilda, PhD, as Chief Scientific Officer
(CSO) replacing Professor René Lafont, co-founder, who will become Scientific
Advisor. René Lafont will continue to be actively involved in the Company's
scientific strategy and will also remain on Biophytis' Scientific Advisory
Board (SAB). Dr. Dilda joined Biophytis in December 2015 as VP Research before
being promoted to CSO. He has more than 20 years of experience in
pharmaceutical research, in both academic and industrial settings (Mayoli
Spindler Laboratories). Prior to joining Biophytis he was Senior Research
Fellow at the Lowy Cancer Research Center at the University of New South Wales
(UNSW) in Sydney, Australia, where he was responsible for advancing several
cancer therapeutics. Pierre has a PhD in Pharmacology from Paris V University.
In one further organizational change, Waly Dioh, PhD, has been appointed to the
newly created role of Chief Operating Officer (COO). Dr. Dioh joined Biophytis
at the inception in 2006 and managed Biophytis' clinical trials as VP Clinical
Development before being promoted to the COO position. As COO he will drive all
aspects of pharmaceutical, regulatory preclinical and early clinical
operations. Prior to joining Biophytis, Waly was at Monsanto, in France and the
U.S. where he ran a regulatory affairs team for the development of
biotechnology products. He has a PhD in Biology from Paris XI University.
Stanislas Veillet, Chief Executive Officer, said:
"I would like to welcome Evelyne to Biophytis as our new CFO and I am confident
that her significant healthcare, financial, strategic and fundraising
experience will allow her to make a significant contribution to the Company's
future success. Pierre and Waly have played a key role in Biophytis' recent
progress and these new promoted roles will allow them to make an even greater
contribution. I am confident that with this strengthened senior management
team, supported by Rene's continuing scientific advice, Biophytis is well
placed to maximize the value that could be created from Sarconeos (BIO101), if
the current SARA-INT Phase 2b clinical trial evaluating its safety and efficacy
in patients with sarcopenia, delivers positive results."
Biophytis is a clinical-stage biotechnology company focused on developing
therapeutics that slow the degenerative processes associated with aging and
improve functional outcomes for patients suffering from age-related diseases,
with a primary focus on neuromuscular diseases.
Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered
small molecule, which is currently in a Phase 2b clinical trial for sarcopenia
(SARA-INT) in the U.S. and Europe. A pediatric formulation of Sarconeos
(BIO101) is being developed for the treatment of Duchenne muscular dystrophy
(DMD). Biophytis expects Sarconeos (BIO101) to be ready to enter the clinic for
DMD in 2020, subject to regulatory approval.
Biophytis is headquartered in Paris, France, and has offices in Cambridge,
Massachusetts. The Company's ordinary shares are listed on Euronext Growth
Paris (Ticker: ALBPS - ISIN : FR0012816825). For more information please visit
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf-france.org) or on Biophytis' website (www.biophytis.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to securities
of Biophytis in any country. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements and estimates,
which speak only as of the date hereof. Other than as required by applicable
law, Biophytis undertakes no obligation to update or revise the information
contained in this press release. This press release has been prepared in both
French and English. In the event of any differences between the two texts, the
French language version shall prevail.
Stanislas Veillet, CEO